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G-band analysis. Partial karyotype showing the 
t(6;8)(q27;p12); courtesy José Luis Vizmanos. 
Clinics and pathology 
Disease 
BCR-ABL negative chronic myeloproliferative disease 
associates with 8p11 chromosomal rearrangements and 
a clinical entity named '8p11 myeloproliferative 
syndrome' (EMS) or 'stem cell leukemia/lymphoma' 
(SCLL) syndrome. These chromosomal rearrangements 
fuse FGFR1 (a receptor tyrosine kinase gene) with 
other genes resulting in new chimeric genes which are 
translated in constitutionally activated FGFR1-like 
proteins. This is a multilineage disorder with combined 
occurrence of myeloid malignancy and T- cell NHL, or 
myeloid metaplasia. 
Phenotype / cell stem origin 
The same t(6;8)(q27;p12) is found both in the bone 
marrow and in the lymph node: the multilineage 
involvement suggests the malignant transformation of a 
primitive hematopoietic stem cell. 
Epidemiology 
Rare, very few cases described with this translocation 
(eight until date, four female and four male). A higher 
number have been described with other FGFR1 fusions, 
mainly t(8;13) and ZNF198-FGFR1 fusion. 
Clinics 
This is a myeloproliferative aggressive disease; 
complex picture of myeloid hyperplasia progressing to 
myelodysplasia and T- lymphoma, and acute non 
lymphocytic leukemia ; enlarged lymph node infiltrated 
by myeloid blast cells; blood data: high WBC (median 
40 X 109l); myelemia; monocytosis and eosinophilia. 
The clinical phenotype at presentation may vary 
between different partner genes involved in the FGFR1 
fusion and, furthermore, between individuals. 
Only eight cases with the t(6;8)(q27;p11) have been 
reported. Four of these patients had features at 
presentation and/or a clinical course typical of EMS: 
malignant T-cell lymphoma and CML, 
AML/myeloproliferative disease, CML-like disease 
with eosinophilia that progressed rapidly to AML, and 
primary AML that evolved to EMS following 
chemotherapy. Two cases presented with polycytemia 
vera (PV), one of them progressed to AML after a 
period of 5 years and the other one progressed to an 
EMS-like myeloproliferative disorder. The remaining 
case reported showed a B-ALL at presentation. This 
phenotype has been also described in the 
transformation phase of some cases with other FGFR1 
fusions. 
Treatment 
EMS or SCLL seems to be refractory to conventional 
chemotherapy and some good results have been 
reached with allogeneic stem cell transplantation. 
Imatinib is not effective against constitutional activated 
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FGFR1, but this disease could be responsive to specific 
FGFR1 inhibitors. 
Evolution 
CR could be obtained, but is promptly followed by 
relapse progressing rapidly to an AML, rarely ALL. 
Prognosis 
Median survival: 6 months. Although the number of 
reported cases is low, EMS seems to be disease with 




Available data shows that sometimes the 
t(6;8)(q27;p12) is not the sole abnormality. 
BM:46,XX,t(6;8)(6pter-6q27::8p12-8pter;6qter-
6q27::8p12-8qter) 
BM: 46,XY,t(6;8)(q27;p11) [100%] 




BM: 46,XX,t(6;8)(q27;p12),+der(6)add(6)(q27)[66% ]; 
46,XX,t(6;8)(q27;p12) [34%] 
BM: 45,XY,t(6;8)(q27;p12),-7 [100%] 
Cytogenetics molecular 
Mega YAC 959-A -4 (1260 kb) from CEPH; FGFR1-
specific cosmid 134.8. 
Variants 
t(6;8)(q27;p12) is one of the reported rearrangements 
of 8p11 that fuses FGFR1 with other partner genes. 
Genes involved and Proteins 
FGFR1 
Location: 8p12 
Note: This gene is involved in several fusions. 
DNA / RNA 
24 exons spanning about 55.9 kb on 8p12. 
Transcription is from centromere to telomere. Based on 
Entrez data, FGFR1OP has seven different transcripts. 
Based on EnsEMBL data it has five different 
transcripts. 
Protein 
According to UniProt-SwissProt FGFR1 
(FGFR1_HUMAN) or fibroblast growth factor receptor 
1 is a receptor for basic fibroblast growth factor located 
in the membrane. Binding of FGF1 and heparin 
promotes autophosphorylation on tyrosine residues and 
activation of the receptor. FGFR1 contains 3 Ig-like 
C2-type (immunoglobulin-like) domains and a protein 
kinase domain. It belongs to the protein tyrosine kinase 
family, fibroblast growth factor receptor subfamily. 
Defects in FGFR1 have been associated with Pfeiffer 
syndrome (PS) or acrocephalosyndactyly type V 
(ACS5), hypogonadotropic hypogonadism (IHH), 
Kallmann syndrome type 2 (KAL2) ; osteoglophonic 
dysplasia (OGD); or osteoglophonic dwarfism, non-
syndromic trigonocephaly or metopic craniosynostosis, 
and the EMS/SCLL due to fusion with other genes and 
constitutive activation of this receptor. 
FGFR1OP (formerly known as FOP, 
FGFR1 oncogene partner) 
Location: 6q27 
Note: This gene is involved only in this fusion. 
DNA / RNA 
13 exons spanning about 43.2 kb on 6q27. 
Transcription is from centromere to telomere. Based on 
Entrez data, FGFR1OP has two different transcripts. 
Based on EnsEMBL-Vega data it has up to 6 different 
transcripts. 
Protein 
According to UniProt-SwissProt FGFR1OP 
(FR1OP_HUMAN) is a centrosomal protein associated 
with gamma-tubulin and required for anchoring 
microtubules to the centrosomes. Other centrosomal 
proteins have been described as fusion partner of 
tyrosine kinases like FGFR1. 
FGFR1OP is a hydrophilic protein that contains several 
leucine-rich regions with consensus sequences L-X2-L-
X3-5-L-X3-5-L (in some of them leucine is substituted 
by either valine or isoleucine) in its amino and carboxy 
termini. It has a putative role as a regulator of normal 
proliferation and differentiation of the erythroid lineage 
and could belong to a novel family of the leucine-rich 
proteins. FGFR1OP also contains a Lis-homology 
(LisH) motif found in more than 100 eukaryotic 
proteins. These motifs are believed to be involved in 
microtubule dynamics and organization, cell migration 
and chromosome segregation; several of them are 
associated with genetic diseases. 
Its expression is ubiquitous but is higher in heart, liver, 
muscle, kidney, intestine, colon, adrenal gland, 
prostate, testis, and pancreas. 




Three different hybrid genes have been described, 
based on different breakpoints on the FGFR1OP gene. 
An in-frame fusion between FGFR1OP exon 6 and 
FGFR1 exon 9 was described; later, two variants in 
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Schematic representation of the fusion FGFR1OP-FGFR1 resulting from the t(6;8)(q27;p12). Top figure courtesy José Luis Vizmanos : 
From top to bottom: structure of FGFR1, FGFR1OP and the putative chimeric FGFR1OP-FGFR1. TM, transmembrane domain; TK, 
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different patients, both in-frame with FGFR1 exon 9, 
one of them involving FGFR1OP exon 5 and the other 
involving FGFR1OP exon 7 was described. 
The presence of two different transcripts (one with a 
breakpoint in FGFR1OP exon 6 and the other with a 
breakpoint in exon 7) was reported. 
Transcript 
5' FGFR1OP-FGFR1 3' 
Detection protocole 
See ref. 4 below. 
Fusion protein 
Description 
The fusion gene is predicted to encode an aberrant 
tyrosine kinase composed of the putative leucine-rich 
N-terminal region of FOP, and the FGFR1 intracellular 
region. Like other fusions involving RTKs, FGFR1OP-
FGFR1 lacks the FGFR1 transmembrane domain. 
Oncogenesis 
Through constitutive activation of FGFR1 signal 
transduction pathways, via putative dimerization of the 
fusion protein via the FOP leucine-rich repeats 
FGFR1OP shares features in common with other 
tyrosine kinase fusion partners, namely widespread 
expression and the presence of putative oligomerization 
domains. There is experimental proof that expression of 
FOP-FGFR1 in primary bone marrow cells induced by 
retroviral transduction generates a rapid MPD in mice. 
However, lymphoproliferation and progression to acute 
phase were not observed in the murine model. 
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